Pneumonia biomarkers
AssigneeUpstream Medical Technologies Limited
InventorsChristopher Joseph PEMBERTON, Arthur Mark RICHARDS, Mathew Simon BYERS
Life of this patent
Estimating the term…
Abstract
Ghrelin signal peptide fragment assays and kits useful in the diagnosis, prognosis, risk stratification, assessing, staging, monitoring, categorizing and determination of further diagnoses and treatment regimens in subjects with various disorders, diseases and conditions including, pneumonia, heart failure, or pneumonia and heart failure or suspected pneumonia, heart failure, or pneumonia and heart failure, and methods for monitoring treatment.
Claims32
A method for evaluating pneumonia infection in a subject, or for evaluating acute decompensated heart failure (ADHF) in a subject, or for evaluating pneumonia and acute decompensated heart failure (ADHF) in a subject, comprising performing an assay method configured to detect a ghrelin signal peptide fragment in a body fluid sample obtained from the subject to provide an assay result;
- and correlating the assay result to the presence or status of a pneumonia infection in the subject or correlating the assay result to the presence or status of acute decompensated heart failure (ADHF) in the subject, or correlating the assay result to the presence or status of pneumonia and acute decompensated heart failure (ADHF) in the subject.
An assay for diagnosing pneumonia, for diagnosing acute decompensated heart failure (ADHF) or for diagnosing pneumonia and acute decompensated heart failure (ADHF) in a subject, comprising:
- (a) binding a ghrelin signal peptide fragment from a biological sample;
- and
- (b) determining the presence or amount of bound ghrelin signal peptide fragment;
- and
- (c) correlating the presence or amount of said bound ghrelin signal peptide fragment with a reference or control value to diagnose whether said subject has pneumonia, ADHF or pneumonia and ADHF,
- wherein a deviation in the presence or amount of bound ghrelin signal peptide fragment in the sample from the reference or control value is indicative of pneumonia, ADHF or pneumonia and ADHF, respectively.
A use of a ghrelin signal peptide fragment binding agent in the manufacture of a prognostic, diagnostic or monitoring assay for assessing pneumonia, acute decompensated heart failure (ADHF) or pneumonia and acute decompensated heart failure (ADHF) in a subject.
A kit for predicting, diagnosing or monitoring pneumonia, acute decompensated heart failure (ADHF) or pneumonia and acute decompensated heart failure (ADHF) comprising a ghrelin signal peptide fragment binding agent;
- and optionally instructions for predicting, diagnosing or monitoring pneumonia, ADHF or pneumonia and ADHF in a subject from the ghrelin signal peptide fragment level measured in a biological sample from the subject.
An isolated GHRsp (1-10) peptide that comprises an amino acid sequence MPSPGTVCSL (SEQ ID NO:
- 4).
An isolated antibody or antigen-binding antibody fragment that binds to GHRsp(1-10) (SEQ ID NO:
- 4).
Dependencies are inferred from the claim text.